Our portfolio company Sirius Medical secures growth funding from new and existing investors to further develop the Sirius Pintuition portfolio and expand international sales
Eindhoven, 4th of February 2025 – Our portfolio company Sirius Medical, a leading medtech company and market leader in oncological surgical marker navigation, has raised €10 million in funding on World Cancer Day. This investment round was led by Invest-NL and Nextgen Ventures, with support from De Groot Family Office and existing investors Brabant Development Agency (BOM), Holland Capital, Curie Capital, Team Holmium, and Sirius Medical’s team.
World Cancer Day is a poignant reminder of the ongoing fight against cancer, and this milestone reflects Sirius Medical’s commitment to enhancing cancer care. Praised by breast cancer surgeons worldwide, the Sirius Pintuition® surgical navigation platform enables simple, best-in-class wire-free localization for breast-conserving surgery in any hospital. This latest funding round empowers Sirius Medical to enhance the Sirius Pintuition system and GPSDetect™ software platform, focusing on usability and intuitiveness, and extending its applications. Additionally, the investment will substantially bolster the sales infrastructure and support expansion into new markets.
“Announcing this funding milestone on World Cancer Day underscores the urgency of our mission to improve cancer care globally,” says Bram Schermers, CEO of Sirius Medical. “This funding round, in the current fundraising environment, is a clear testament to the talent of the Sirius Medical team, and the Pintuition technology that we have developed. We are proud to continue contributing to the fight against cancer and look forward to the next phase of growth for Sirius Medical. We will have more exciting news to announce soon.”
“From Holland Capital, we have been supporting Sirius Medical for many years to bridge the notorious ‘valley of death,’” said Jan Frens van Giessel, partner at Holland Capital. “Many young companies in medical technology fail due to a lack of funding, as reported by Financieele Dagblad a few weeks ago. For investors, investing in medical technology is risky because the development and sales processes are complex, uncertain, and lengthy. We experience this at Holland Capital as well, but when a company manages to distinguish itself and achieves key technical and commercial milestones, we do everything we can to arrange financing. This is also the case with Sirius Medical.”
“We have seen Sirius Medical grow over the years into a successful med-tech scale-up, with sales in the US, UK, almost all EU countries, and Australia. We are proud of the impressive results the Sirius Medical team has achieved. We welcome the new investors, NextGen and InvestNL, so that together we can make this Dutch healthcare innovation available to women with breast cancer worldwide,” said Jan Frens van Giessel, partner at Holland Capital.
About World Cancer Day
World Cancer Day, observed on February 4th, is a global initiative to raise awareness, inspire action, and work together to reduce the impact of cancer worldwide.
About Sirius Medical
With its roots in the Netherlands Cancer Institute, Sirius Medical is dedicated to improving care for cancer patients by delivery of unsurpassed, yet affordable solutions that enable precise and efficient removal of tumors. Sirius Pintuition is precise, simple, affordable and both CE marked, and FDA cleared. Sirius Medical is rapidly expanding with over 250 centers and 35.000 procedures globally.
Investeerder Holland Venture trekt EUR 55 miljoen aan voor nieuw private equity fonds
Amsterdam, 13 december 2016 – Holland Venture is een nieuw private equity fonds gestart. Het kapitaal is bedoeld voor middelgrote Nederlandse ondernemingen die actief zijn in de sectoren Healthcare en Technology. De fundraising verliep voortvarend; binnen drie maanden...
Holland Venture raises 55 million for a new private equity fund
Amsterdam, 13th of December 2016 - Holland Venture has launched a new private equity fund. The capital is intended for small and medium-sized Dutch companies operating in the fields of Healthcare and Technology. The fundraising went expeditiously; the target amount of...
Holland Venture investeert in cloud en security specialist Avensus Nederland BV
Amsterdam, 28 november 2016 – Investeringsmaatschappij Holland Venture investeert in cloud en security specialist Avensus. De investering steunt Avensus om verdere groei binnen de financiële wereld en de zorgsector te realiseren en haar technologische expertise binnen...
Holland Venture invests in cloud & security specialist Avensus Netherlands BV
Amsterdam, November 28th, 2016 - Holland Venture invests in cloud and security specialist Avensus. The investment supports Avensus to achieve further growth in the financial and healthcare sector and to further develop its technological expertise in cloud and...
Dankzij investering in Prolira BV door Holland Venture en Health Innovations wordt snelle detectie van delirium (delier) mogelijk
27 SEPTEMBER 2016: Met een financiële injectie, kennis en een groot netwerk in de zorg helpen Holland Venture, Health Innovations en twee business angels om de Delirium Monitor van Prolira tot de nieuwe internationale gouden standaard voor detectie van delirium te...
Thanks to investment in Prolira BV, by Holland Venture and Health Innovations, early detection of delirium will be possible.
27 SEPTEMBER 2016: With a cash injection, knowledge and a large network in healthcare, Holland Venture, Health Innovations and two business angels are helping to make Prolira’s Delirium Monitor the new international standard for detection of delirium.Delirium, an...
Amsterdam
Krijn Taconiskade 426
1087 HW Amsterdam
+31 (0) 20 3119411
Düsseldorf
Königsallee 42
40212 Düsseldorf
+49 (0) 211 96290120
Contact
info@hollandcapital.nl